Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ARS Pharmaceuticals, Inc.SPRY · Entity 883 | Director · PRESIDENT AND CEO · 10% owner | January 02, 2026 | January 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ARS Pharmaceuticals, Inc.
Report date January 02, 2026 · Filed January 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.49 · Expires 2036-01-01 | Direct | 875,000 |
Reported balance
After 2026-01-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-02 · Grant · Acquired 875,000 · Balance 875,000 F1: The shares subject to the option shall vest in a series of 48 equal monthly installments measured from January 1, 2026. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.49 · Expires 2036-01-01 | IndirectBy Spouse | 240,000 |
Reported balance
After 2026-01-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-02 · Grant · Acquired 240,000 · Balance 240,000 F1: The shares subject to the option shall vest in a series of 48 equal monthly installments measured from January 1, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option shall vest in a series of 48 equal monthly installments measured from January 1, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 08, 2022 Filed Nov 10, 2022 23:00 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | GrantEmployee Stock Option (Right to Buy) · Derivative | 82,733 | Not disclosed Strike: $0.84 | Not disclosed |
DisclosureSEC source: 0001209191-22-056442 · doc4.xml · derivative · entry 7 Lowenthal Richard E · CIK 0001378550 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 82,733 Underlying: Common Stock · 82,733 shares Expires 2029-12-16 F8 · price: Upon the closing of the Merger, each outstanding option to purchase shares of ARS common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock. F10 · price: Received in exchange for a stock option to acquire 70,000 shares of common stock of ARS with an exercise price of $0.99 per share pursuant to the Merger Agreement. F6 · derivative.exercise_date: 25% of the shares subject to the option vest on the one year anniversary of the vesting commencement date and the balance of the shares vest in a series of thirty-six (36) successive equal monthly installments measured from the first anniversary of the vesting commencement date. Read SEC document |
| November 08, 2022 Filed Nov 10, 2022 23:00 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | GrantEmployee Stock Option (right to buy) · Derivative | 236,380 | Not disclosed Strike: $1.44 | Not disclosed |
DisclosureSEC source: 0001209191-22-056442 · doc4.xml · derivative · entry 6 Lowenthal Richard E · CIK 0001378550 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 236,380 Underlying: Common Stock · 236,380 shares Expires 2031-12-13 F8 · price: Upon the closing of the Merger, each outstanding option to purchase shares of ARS common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock. F9 · price: Received in exchange for a stock option to acquire 200,000 shares of common stock of ARS with an exercise price of $1.70 per share pursuant to the Merger Agreement. F6 · derivative.exercise_date: 25% of the shares subject to the option vest on the one year anniversary of the vesting commencement date and the balance of the shares vest in a series of thirty-six (36) successive equal monthly installments measured from the first anniversary of the vesting commencement date. Read SEC document |
| November 08, 2022 Filed Nov 10, 2022 23:00 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | GrantEmployee Stock Option (right to buy) · Derivative | 236,380 | Not disclosed Strike: $0.84 | Not disclosed |
DisclosureSEC source: 0001209191-22-056442 · doc4.xml · derivative · entry 5 Lowenthal Richard E · CIK 0001378550 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 236,380 Underlying: Common Stock · 236,380 shares Expires 2029-12-16 F7 · price: Received in exchange for a stock option to acquire 200,000 shares of common stock of ARS with an exercise price of $0.99 per share pursuant to the Merger Agreement. F8 · price: Upon the closing of the Merger, each outstanding option to purchase shares of ARS common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock. F6 · derivative.exercise_date: 25% of the shares subject to the option vest on the one year anniversary of the vesting commencement date and the balance of the shares vest in a series of thirty-six (36) successive equal monthly installments measured from the first anniversary of the vesting commencement date. Read SEC document |
| November 08, 2022 Filed Nov 10, 2022 23:00 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | GrantCommon Stock | 1,772,850 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-056442 · doc4.xml · nonDerivative · entry 4 Lowenthal Richard E · CIK 0001378550 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Sarina Tanimoto Charitable Remainder Unitrust Dated January 7, 2020 Disclosed balance after: 1,772,850 F2 · price: Received in exchange for 1,500,000 shares of common stock of ARS pursuant to the Merger Agreement. F5 · ownership.nature: The Reporting Person's spouse is trustee of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| November 08, 2022 Filed Nov 10, 2022 23:00 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | GrantCommon Stock | 4,326,854 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-056442 · doc4.xml · nonDerivative · entry 3 Lowenthal Richard E · CIK 0001378550 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 4,326,854 F4 · price: Received in exchange for 3,660,930 shares of common stock of ARS pursuant to the Merger Agreement. Read SEC document |
| November 08, 2022 Filed Nov 10, 2022 23:00 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | GrantCommon Stock | 1,772,850 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-056442 · doc4.xml · nonDerivative · entry 2 Lowenthal Richard E · CIK 0001378550 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Richard E. Lowenthal Charitable Remainder Unitrust Dated January 7, 2020 Disclosed balance after: 1,772,850 F2 · price: Received in exchange for 1,500,000 shares of common stock of ARS pursuant to the Merger Agreement. F3 · ownership.nature: The Reporting Person is trustee of the trust. Read SEC document |
| November 08, 2022 Filed Nov 10, 2022 23:00 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | GrantCommon Stock | 5,176,822 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-056442 · doc4.xml · nonDerivative · entry 1 Lowenthal Richard E · CIK 0001378550 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,176,822 F1 · price: Received in exchange for 4,380,084 shares of common stock of ARS Pharmaceuticals, Inc. ("ARS") pursuant to an Agreement and Plan of Merger and Reorganization by and among ARS, the Issuer and Sabre Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"), as amended (the "Merger Agreement"). Under the terms of the Merger Agreement, on November 8, 2022, Merger Sub merged with and into ARS (the "Merger"), with ARS surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of ARS common stock was converted into the right to receive 1.1819 shares of the Issuer common stock. Subsequent to the Merger, the name of the Issuer was changed from Silverback Therapeutics, Inc. to ARS Pharmaceuticals, Inc. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.